Wyatt Stephanie N, Rhoads Sarah J
College of Medicine, Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Adv Neonatal Care. 2006 Aug;6(4):175-80. doi: 10.1016/j.adnc.2006.04.002.
Parents and healthcare providers are challenged to understand the mechanisms of, and predictors for preterm delivery. In addition to the epidemiologic implications, on a practical level, the ability to predict preterm delivery may help the neonatal team triage to assure bed availability, and to predict and provide appropriate staffing for new admissions. On an individual patient level, understanding the maternal history, including antenatal risk factors and relevant monitoring and testing, is an important foundation for subsequent neonatal care. A number of new diagnostic testing tools are being used in obstetric practice to enhance the ability to predict preterm delivery. The results of fetal fibronectin and ultrasound measurement of cervical length are increasingly used to triage obstetrical patients. Results of these tests may prompt transfer to a tertiary facility. Part 1 of this 2-part series will describe antenatal testing techniques used to predict preterm delivery (PTD), as well as highlight the emerging developments in maternal serum testing. Further, a recent treatment option for preterm labor, 17 alpha-hydroxyprogesterone caproate, will also be discussed.
父母和医疗保健提供者面临着理解早产机制和预测因素的挑战。除了流行病学意义外，从实际层面来看，预测早产的能力可能有助于新生儿团队进行分诊，以确保床位可用，并为新入院患者预测并提供适当的人员配置。在个体患者层面，了解产妇病史，包括产前危险因素以及相关监测和检测，是后续新生儿护理的重要基础。产科实践中正在使用一些新的诊断测试工具来提高预测早产的能力。胎儿纤连蛋白检测结果和宫颈长度超声测量越来越多地用于产科患者的分诊。这些测试结果可能会促使患者转诊至三级医疗机构。这个两部分系列的第一部分将描述用于预测早产（PTD）的产前检测技术，并突出母血清检测的新进展。此外，还将讨论早产的一种最新治疗选择——己酸17α-羟孕酮。
